JOP20190001A1 - عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه - Google Patents

عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Info

Publication number
JOP20190001A1
JOP20190001A1 JOP/2019/0001A JOP20190001A JOP20190001A1 JO P20190001 A1 JOP20190001 A1 JO P20190001A1 JO P20190001 A JOP20190001 A JO P20190001A JO P20190001 A1 JOP20190001 A1 JO P20190001A1
Authority
JO
Jordan
Prior art keywords
adrenomedullin
polyethylene glycol
based prodrug
glycol based
diseases
Prior art date
Application number
JOP/2019/0001A
Other languages
English (en)
Inventor
Johannes K?Bberling Dr
Ingo Flamme Dr
Hans-Georg Lerchen Dr
Sven Wittrock Dr
Koellnberger Maria
Nils Griebenow Dr
Frank Wunder Dr
Rudolf Schohe-Loop Dr
Gorden Redlich Dr
Iain Pritchard Dr
Andreas Knorr Dr
Julie Marley Dr
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of JOP20190001A1 publication Critical patent/JOP20190001A1/ar
Application granted granted Critical
Publication of JOP20190001B1 publication Critical patent/JOP20190001B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

يتعلق الاختراع بعقار معتمد على polyethylene glycol (PEG) جديد من adrenomedullin، بعمليات لتحضيره، باستخدام ذلك لمعالجة و/أو منع أمراض، واستخدام ذلك لإنتاج أدوية من أجل معالجة و/أو منع أمراض، خصوصا اضطرابات قلبية وعائية، أوديمية و/أو التهابية.
JOP/2019/0001A 2011-11-03 2011-11-03 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه JOP20190001B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187735 2011-11-03

Publications (2)

Publication Number Publication Date
JOP20190001A1 true JOP20190001A1 (ar) 2017-06-16
JOP20190001B1 JOP20190001B1 (ar) 2022-03-14

Family

ID=47146369

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2019/0001A JOP20190001B1 (ar) 2011-11-03 2011-11-03 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
JOP/2012/0324A JO3385B1 (ar) 2011-11-03 2012-10-24 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2012/0324A JO3385B1 (ar) 2011-11-03 2012-10-24 عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه

Country Status (45)

Country Link
US (3) US9603936B2 (ar)
EP (2) EP3075395B1 (ar)
JP (2) JP5995984B2 (ar)
KR (2) KR102004668B1 (ar)
CN (2) CN103998063B (ar)
AR (2) AR088582A1 (ar)
AU (2) AU2012331244B2 (ar)
BR (1) BR112014010708B1 (ar)
CA (1) CA2854134C (ar)
CL (1) CL2014000948A1 (ar)
CO (1) CO7020863A2 (ar)
CR (1) CR20140184A (ar)
CU (1) CU24184B1 (ar)
CY (2) CY1117354T1 (ar)
DK (2) DK2773376T3 (ar)
DO (2) DOP2014000078A (ar)
EA (2) EA029410B1 (ar)
EC (2) ECSP14013326A (ar)
ES (2) ES2568063T3 (ar)
GT (1) GT201400085A (ar)
HK (1) HK1246147A1 (ar)
HR (2) HRP20160285T1 (ar)
HU (2) HUE036535T2 (ar)
IL (3) IL232037B (ar)
IN (1) IN2014CN03290A (ar)
JO (2) JOP20190001B1 (ar)
LT (1) LT3075395T (ar)
MA (1) MA35618B1 (ar)
ME (1) ME02379B (ar)
MX (2) MX350341B (ar)
MY (2) MY194197A (ar)
NO (1) NO3075395T3 (ar)
PE (2) PE20181493A1 (ar)
PL (2) PL2773376T3 (ar)
PT (1) PT3075395T (ar)
RS (2) RS54623B1 (ar)
SG (2) SG10201607516SA (ar)
SI (2) SI2773376T1 (ar)
TN (1) TN2014000185A1 (ar)
TR (1) TR201802124T4 (ar)
TW (2) TWI583396B (ar)
UA (1) UA111098C2 (ar)
UY (2) UY37922A (ar)
WO (1) WO2013064508A1 (ar)
ZA (1) ZA201600434B (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커
EP2896400A1 (en) * 2014-01-17 2015-07-22 Université Catholique De Louvain Method for increasing the bioavailability of inhaled compounds
JP6685046B2 (ja) * 2014-03-20 2020-04-22 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
AP2017009826A0 (en) * 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
KR102152437B1 (ko) 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 장시간 작용형 아드레노메둘린 유도체
EP3604538A4 (en) * 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
GB201707938D0 (en) * 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN114174326A (zh) 2019-06-18 2022-03-11 拜耳公司 长期稳定的肾上腺髓质素类似物及其用途
WO2021112220A1 (ja) * 2019-12-05 2021-06-10 国立大学法人 宮崎大学 異常タンパク質蓄積性神経変性疾患の治療剤
WO2021198327A1 (en) 2020-04-03 2021-10-07 Bayer Aktiengesellschaft Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use
JP2023520543A (ja) 2020-04-03 2023-05-17 バイエル アクチェンゲゼルシャフト 医薬製剤であるアドレノメデュリンのポリエチレングリコールベースのプロドラッグおよび使用
MX2023002850A (es) 2020-09-10 2023-07-07 Precirix N V Fragmento de anticuerpo contra proteina activadora de fibroblastos (fap).
CN112457218B (zh) * 2020-11-05 2022-08-09 宁夏医科大学 2,4-二氨基丁酸衍生物的合成方法
IL310248A (en) 2021-08-20 2024-03-01 Bayer Ag A process for the preparation of polyethylene glycol-modified adrenomedullin, its intermediates and their use
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5020040A (en) * 1987-06-24 1991-05-28 Digital Equipment Corporation Overwriting system for magneto-optical recording with self timing track
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
CA2292902C (en) 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
WO2005009768A1 (en) 2003-07-23 2005-02-03 Meggitt Aerospace Equipment Composite seal
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
ATE534664T1 (de) 2004-05-24 2011-12-15 Inst Cardiologie Montreal Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
CA2686760C (en) 2007-05-11 2016-10-11 Institut De Cardiologie De Montreal Labelled adrenomedullin derivatives and their use for imaging and therapy
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
KR20150000464A (ko) * 2011-11-03 2015-01-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 펩티드의 방출가능한 연결을 위한 티로신 기재의 링커

Also Published As

Publication number Publication date
EP3075395B1 (en) 2017-11-22
JP5995984B2 (ja) 2016-09-21
MX350341B (es) 2017-09-04
CR20140184A (es) 2014-05-27
HUE027333T2 (en) 2016-09-28
US20160367636A1 (en) 2016-12-22
BR112014010708B1 (pt) 2021-03-02
RS54623B1 (en) 2016-08-31
MY194197A (en) 2022-11-21
US20170204137A1 (en) 2017-07-20
ZA201600434B (en) 2017-05-31
CY1117354T1 (el) 2017-04-26
US10035818B2 (en) 2018-07-31
TR201802124T4 (tr) 2018-03-21
PL3075395T3 (pl) 2018-04-30
JP6177975B2 (ja) 2017-08-09
PL2773376T3 (pl) 2016-07-29
CA2854134A1 (en) 2013-05-10
PT3075395T (pt) 2018-02-13
AR088582A1 (es) 2014-06-18
ES2568063T3 (es) 2016-04-27
EP2773376A1 (en) 2014-09-10
HK1246147A1 (zh) 2018-09-07
AU2012331244B2 (en) 2017-06-15
CU24184B1 (es) 2016-07-29
ECSP14013326A (es) 2014-05-31
MX2014004384A (es) 2014-04-30
MY173372A (en) 2020-01-21
IN2014CN03290A (ar) 2015-07-03
JOP20190001B1 (ar) 2022-03-14
MX361287B (es) 2018-12-03
TN2014000185A1 (en) 2015-09-30
SG10201607516SA (en) 2016-10-28
BR112014010708A2 (pt) 2017-04-25
TWI653051B (zh) 2019-03-11
US9603936B2 (en) 2017-03-28
EP2773376B1 (en) 2016-01-13
JP2014532682A (ja) 2014-12-08
EA029410B1 (ru) 2018-03-30
EA025631B1 (ru) 2017-01-30
KR20180108892A (ko) 2018-10-04
NZ714621A (en) 2017-10-27
IL258229B (en) 2020-02-27
KR20150000462A (ko) 2015-01-02
ME02379B (me) 2016-06-20
WO2013064508A1 (en) 2013-05-10
IL258229A (en) 2018-06-28
CN107412740B (zh) 2021-02-09
HUE036535T2 (hu) 2018-07-30
ES2659195T3 (es) 2018-03-14
CO7020863A2 (es) 2014-08-11
TW201720467A (zh) 2017-06-16
CL2014000948A1 (es) 2014-09-05
CY1119897T1 (el) 2018-06-27
HRP20160285T1 (hr) 2016-04-22
IL252281B (en) 2021-01-31
CN103998063B (zh) 2016-09-21
GT201400085A (es) 2015-03-05
TW201332573A (zh) 2013-08-16
JP2017014264A (ja) 2017-01-19
CA2854134C (en) 2020-04-21
NO3075395T3 (ar) 2018-04-21
CN103998063A (zh) 2014-08-20
AU2017203423A1 (en) 2017-06-08
PE20181493A1 (es) 2018-09-18
CN107412740A (zh) 2017-12-01
MA35618B1 (fr) 2014-11-01
US9649363B2 (en) 2017-05-16
AR113830A2 (es) 2020-06-17
JO3385B1 (ar) 2019-03-13
ECSP18071104A (es) 2018-10-31
EA201600495A1 (ru) 2016-10-31
IL232037A0 (en) 2014-05-28
HRP20180319T1 (hr) 2018-03-23
EP3075395A1 (en) 2016-10-05
IL252281A0 (en) 2017-08-31
NZ622997A (en) 2015-12-24
SG11201400924TA (en) 2014-09-26
US20140287984A1 (en) 2014-09-25
UA111098C2 (uk) 2016-03-25
LT3075395T (lt) 2018-02-26
EA201400528A1 (ru) 2014-10-30
IL232037B (en) 2018-12-31
PE20141219A1 (es) 2014-09-13
TWI583396B (zh) 2017-05-21
AU2017203423B2 (en) 2019-01-31
DOP2018000203A (es) 2018-10-15
SI2773376T1 (sl) 2016-05-31
KR102004668B1 (ko) 2019-07-26
SI3075395T1 (en) 2018-03-30
RS56819B1 (sr) 2018-04-30
UY37922A (es) 2018-11-30
AU2012331244A1 (en) 2014-04-17
KR101965467B1 (ko) 2019-04-03
UY34419A (es) 2013-05-31
DK2773376T3 (en) 2016-04-18
DOP2014000078A (es) 2014-07-15
CU20140051A7 (es) 2014-10-02
DK3075395T3 (en) 2018-02-19

Similar Documents

Publication Publication Date Title
TN2014000185A1 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
TN2015000278A1 (en) Autotaxin inhibitors
PH12016500094A1 (en) Autotaxin inhibitors
WO2014096425A3 (en) Prodrugs of monomethyl fumarate (mmf)
MX349004B (es) Nuevos compuestos.
TN2011000466A1 (en) Substituted 2-acetamido -5-aryl-1, 2, 4- triazolones and use thereof
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
GB201118656D0 (en) New compounds
WO2012174158A3 (en) Administration of benzodiazepine
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.